Key Takeaways
- Flat quarter, guidance intact: Revenue declined 2% YoY to ₹790 crore, described as "broadly flat, in line with our expectations," and the company remains on track to hit its full-year guidance range.
- US biotech funding is the swing factor: The revenue decline reflects the two-year dip in US biotech funding, but funding values improved markedly in H1 2024; the lag before that money reaches outsourcing contracts is the core watchpoint.
- Margins compressed sharply: EBITDA from operations margin fell 471 bps YoY to 21.5%, driven by staff costs rising to 32.0% of revenue and material costs rising to 29.6%.
- Capacity bet is loading: The Stelis Biopharma facility repurposing remains on schedule for H2 FY2025 completion, a move that will triple biologics manufacturing capacity and add a high-speed fill-finish line.
- What to watch next quarter: Whether the pilot projects from pharma clients exploring China-plus-one outsourcing convert into larger-scale collaborations, and any early signs that improved US biotech funding is translating into Discovery Services orders.
US Biotech Funding & Demand Recovery
- The drag: A two-year dip in US biotech funding has suppressed Discovery Services revenue, the segment most exposed to early-stage R&D outsourcing by smaller, funded biotechs.
- The green shoot: The value of US biotech funding improved markedly in H1 2024, but management is explicit that it will take time for that funding to flow through into outsourcing contracts.
- Pilot projects as leading indicator: The quarter saw the start of several pilot projects for pharma clients exploring outsourcing options beyond China; successful delivery is expected to build a foundation for larger-scale future collaborations.
- Recovery timing is back-half weighted: Momentum is expected to build in the second half of the year, consistent with the lag between funding rounds and R&D outsourcing decisions.
Hunt: "The value of US biotech funding has seen a marked improvement in the first half of 2024. It will take a while for this funding to flow through into outsourcing activities and Syngene is in a strong position to capture a significant share of the upturn in biotech spending in the months ahead."
Margin Walk
- Staff costs drove the compression: Staff costs rose 10.3% YoY to 252.4 crore, with cost as a percentage of revenue climbing to 32.0% from 28.3%, the single largest margin headwind.
- Material costs added pressure: Material costs rose 4.8% YoY to 233.5 crore, with cost as a percentage of revenue increasing to 29.6% from 27.6%.
- Forex provided a partial offset: Net forex loss narrowed 78.7% YoY to 3.3 crore from 15.5 crore, cushioning the operating cost increases.
- Depreciation tailwind is one-time: Depreciation charge reduced by ₹5.1 crore due to a revision of the estimated useful life of manufacturing assets effective 1 April 2024, a non-cash benefit that will not repeat.
- PAT hit harder than EBITDA: PAT before exceptional item fell 42% YoY to ₹55 crore, with PAT margin before exceptional item falling to 7% from 11%, reflecting the operating deleverage flowing through.
Capacity Expansion: Stelis Facility
- Strategic rationale: The acquired Stelis Biopharma facility, once repurposed, will triple Syngene's biologics manufacturing capacity, a bet that the biotech funding recovery and China-plus-one shift will drive demand for large-molecule CDMO services.
- Timeline: Completion of qualification and facility modifications is expected in H2 FY2025, keeping the asset on track to contribute in the next fiscal year.
- Capability add: The facility includes a high-speed, high-volume fill-finish line, expanding Syngene's offering beyond drug substance into drug product manufacturing.
Segment-Level Dynamics
- Discovery Services: Revenue was hit by the US biotech funding dip, but the quarter was marked by the start of several pilot projects for pharma clients exploring outsourcing options beyond China, a potential leading indicator of a China-plus-one pivot.
- Development Services: Continued to attract repeat business from existing clients, reflecting high standards of service delivery and providing a stable base while Discovery Services waits for the funding recovery.
- Dedicated Centers and Biologics Manufacturing Services: Reported steady growth during the quarter, suggesting the larger, more annuity-like client relationships are holding up better than the transactional Discovery business.
Strategic Positioning & Investments
- China-plus-one opportunity: Management frames current geopolitical shifts as a substantial opportunity, with pilot projects from pharma clients testing outsourcing options beyond China as the first tangible evidence of this dynamic playing out.
- Technology investment underway: The company is investing in technology and capabilities to position favorably for the expected upturn, though specific investment amounts or areas beyond the Stelis facility were not quantified.
- Protein production platform launched: A new platform that reduces development timelines by months for a variety of biologics including monoclonal antibodies, biosimilars, antibody drug conjugates and other recombinant proteins was introduced during the quarter.
- Board addition: Manja Boerman appointed as an independent Non-Executive Director effective June 4, 2024, subject to shareholder approval.
Biswas: "The current industry dynamics, particularly the geopolitical shifts, present a substantial opportunity for our organization. We continue to generate strong cash flows and our balance sheet is robust. We are investing in technology and capabilities that will position us favorably to leverage the opportunity and capture an increased market share."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year guidance | On track to hit guidance range, with momentum building in H2 | FY25 |
| Stelis facility operational | Completion of qualification and facility modifications; will triple biologics capacity and add fill-finish line | H2 FY2025 |
| China-plus-one pilot conversion | Successful delivery of pilot projects to build foundation for larger-scale future collaborations | Undated (dependent on pilot outcomes) |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Revenue from operations | ₹790 cr, -2% YoY |
| Reported revenue | ₹808 cr, -3% YoY |
| EBITDA from operations | ₹170 cr, -19.8% YoY |
| EBITDA from operations margin | 21.5%, vs 26.2% in Q1 FY24, -471 bps |
| EBIT from operations | ₹63 cr, -42.7% YoY |
| EBIT from operations margin | 8.0%, vs 13.6% in Q1 FY24, -562 bps |
| PAT before exceptional item | ₹55 cr, -41.7% YoY |
| PAT margin before exceptional item | 6.7%, vs 11.2% in Q1 FY24, -449 bps |
| Reported PAT | ₹76 cr, -19% YoY |
| Reported PAT margin | 9%, vs 11% in Q1 FY24 |
| Exceptional item, net gain | ₹21 cr (net of tax), final insurance settlement from 2016 fire incident |
| Staff costs | ₹252 cr, 32.0% of revenue from operations, +10.3% YoY |
| Material costs | ₹234 cr, 29.6% of revenue from operations, +4.8% YoY |
| Cash and cash equivalents | ₹107 cr as of 30 June 2024, vs ₹86 cr as of 31 March 2024 |
| Total equity | ₹4,370 cr as of 30 June 2024, vs ₹4,258 cr as of 31 March 2024 |